CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
This meta-analysis synthesized data from 11 phase 3 clinical trials to evaluate the efficacy of CDK4/6 inhibitors in patients with hormone receptor-positive, HER2-negative advanced breast cancer. The analysis included a total of 6035 patients. The study compared the use of CDK4/6 inhibitors, specifically abemaciclib, ribociclib, palbociclib, and dalpiciclib, in combination with endocrine therapy against the use of endocrine monotherapy alone.
The primary outcomes assessed were progression-free survival (PFS) and overall survival (OS). In patients with endocrine-sensitive cancer, the addition of CDK4/6 inhibitors significantly improved PFS with a hazard ratio (HR) of 0.57 (95% CI 0.52-0.63; p<0.0001) and significantly improved OS with an HR of 0.83 (95% CI 0.74-0.92; p=0.0005). For patients with endocrine-resistant cancer, the combination therapy also showed significant improvements, with a PFS HR of 0.51 (95% CI 0.45-0.57; p<0.0001) and an OS HR of 0.77 (95% CI 0.67-0.89; p=0.0003).
Detailed analysis by specific agent revealed varying degrees of-effect. For progression-free survival, abemaciclib demonstrated an HR of 0.53 (95% CI 0.46-0.61; p<0.0001), ribociclib showed an HR of 0.60 (95% CI 0.52-0.68; p<0.0001), palbociclib showed an HR of 0.56 (95% CI 0.49-0.65; p<0.0001), and dalpiciclib showed an HR of 0.49 (95% CI 0.40-0.61; p<0.0001). Regarding overall survival, abemaciclib was associated with an HR of 0.79 (95% CI 0.67-0.92; p=0.0031) and ribociclib was associated with an HR of 0.73 (95% CI 0.64-0.84; p<0.0001). In contrast, the overall survival benefit for palbociclib did not reach statistical significance, with an HR of 0.89 (95% CI 0.77-1.02; p=0.0920). Data regarding overall survival for dalpiciclib remain immature.
Safety and tolerability data, including specific rates of adverse events, serious adverse events, and treatment discontinuation rates, were not reported in this meta-analysis. Consequently, a comprehensive comparison of the toxicity profiles between these agents cannot be performed based solely on the provided data.
This meta-analysis provides a high-level synthesis of existing phase 3 evidence, reinforcing the established role of CDK4/6 inhibitors in this patient population. However, several methodological limitations must be considered. The certainty of the pooled effect sizes was not formally assessed in this abstract, and the results are based on reconstructed individual patient data. Furthermore, the lack of mature data for dalpiciclib overall survival and the absence of reported toxicity profiles limit the ability to perform a complete clinical comparison of all agents.
For clinical practice, these findings suggest that the addition of a CDK4/6 inhibitor to endocrine therapy provides significant survival benefits across different endocrine-sensitivity profiles in advanced HR-positive, HER2-negative breast cancer. However, clinicians must recognize that further head-to-head comparisons, detailed assessments of toxicity profiles, and evaluations of patient-reported outcomes are necessary to guide specific agent selection. Questions remain regarding the long-term comparative safety and the impact of these therapies on quality of life.
More on hormone receptor-positive, HER2-negative advanced breast cancer
View Original Abstract ↓
Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer.
Digital mental health tools may help breast cancer patients feel better
Related in Oncology
From Other Specialties
